nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2015-3-93-97nnp-538Research ArticlePHARMACOTHERAPYФАРМАКОТЕРАПИЯExperience in using levodopa-benserazideОпыт применения леводопы-бенсеразидаКатунинаЕлена АнатольевнаKatuninaElena Anatolyevna

Кафедра неврологии, нейрохирургии и медицинской генетики,

117997, Москва, ул. Островитянова, 1

Department of Neurology, Neurosurgery, and Medical Genetics, 

1, Ostrovityanov St., Moscow 117997

elkatunina@mail.ruБездольныйЮ. Н.BezdolnyiYu. N.

Кафедра неврологии, нейрохирургии и медицинской генетики,

117997, Москва, ул. Островитянова, 1

Department of Neurology, Neurosurgery, and Medical Genetics, 

1, Ostrovityanov St., Moscow 117997

МалыхинаЕ. А.MalykhinaE. A.

Кафедра неврологии, нейрохирургии и медицинской генетики,

117997, Москва, ул. Островитянова, 1

Department of Neurology, Neurosurgery, and Medical Genetics, 

1, Ostrovityanov St., Moscow 117997

ТитоваН. В.TitovaN. V.

Кафедра неврологии, нейрохирургии и медицинской генетики,

117997, Москва, ул. Островитянова, 1

Department of Neurology, Neurosurgery, and Medical Genetics, 

1, Ostrovityanov St., Moscow 117997

ГБОУ ВПО «Российский национальный исследовательский университет им. Н.И. Пирогова» Минздрава РоссииРоссияN.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaRussian Federation201528102015739397Copyright © Katunina E.A., Bezdolnyi Y.N., Malykhina E.A., Titova N.V., 20152015Катунина Е.А., Бездольный Ю.Н., Малыхина Е.А., Титова Н.В.Katunina E.A., Bezdolnyi Y.N., Malykhina E.A., Titova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/538

Levodopa remains the most effective drug for the treatment of Parkinson's disease. The paper considers the mechanism of action, recommended levodopa doses, the time of therapy initiation, and risk factors for motor complications. A few dosage forms of levodopa are currently being used. The results of comparative trials of levodopa-benserazide and levodopa-carbidopa and the clinical experience with Levodopa/Benserazide-Teva are given. An open-label multicenter trial of Levodopa/Benserazide-Teva has shown its high efficacy and good tolerability.

Леводопа остается самым эффективным препаратом для лечения болезни Паркинсона. В статье рассматриваются механизм действия, рекомендуемые дозы леводопы и сроки начала терапии, факторы риска моторных осложнений. В настоящее время применяются несколько форм леводопы. Приводятся результаты сравнительных исследований леводопы-бенсеразида и леводопы-карбидопы, а также клинический опыт применения препарата леводопа/бенсеразид-Тева. Результаты открытого мультицентрового исследования препарата Леводопа/Бенсеразид-Тева показали его высокую эффективность и хорошую переносимость.

леводопа-бенсеразидклиническая эффективностьболезнь Паркинсонаlevodopa-benserazideclinical efficacyParkinson's diseaseООО «Тева»ReferencesSalat D, Tololsa E. Levodopa in Treatment of Parkinson’s Disease: Current Status and New Developments. J Parkinsons Dis. 2013 Jan 1;3(3):255-69. doi: 10.3233/JPD-130186.Salat D, Tololsa E. Levodopa in Treatment of Parkinson’s Disease: Current Status and New Developments. J Parkinsons Dis. 2013 Jan 1;3(3):255-69. doi: 10.3233/JPD-130186.Chaudhuri KR, Glough CG, Sethi KD. Parkinson’s disease. Health Press. 2011;144:11-7.Chaudhuri KR, Glough CG, Sethi KD. Parkinson’s disease. Health Press. 2011;144:11-7.Poewe W, Antonini A. Novel formulation and modes delivery of levodopa. Mov Disord. 2015 Jan;30(1):114-20. doi: 10.1002/mds.26078. Epub 2014 Dec 5.Poewe W, Antonini A. Novel formulation and modes delivery of levodopa. Mov Disord. 2015 Jan;30(1):114-20. doi: 10.1002/mds.26078. Epub 2014 Dec 5.Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002 Feb 26;58(4 Suppl 1):S19-32.Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002 Feb 26;58(4 Suppl 1):S19-32.Blanchet PJ. The fluctuating parkinsonian patient – clinical and pathophysiological aspects. Can J Neurol Sci. 2003 Mar;30 Suppl 1:S19-26.Blanchet PJ. The fluctuating parkinsonian patient – clinical and pathophysiological aspects. Can J Neurol Sci. 2003 Mar;30 Suppl 1:S19-26.Verhagen Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord. 2000 Jan;15(1):3-8.Verhagen Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord. 2000 Jan;15(1):3-8.Катунина ЕА, Авакян ГН, Титова НВ и др. Леводопа – от создания к новым разработкам. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010;(4)110:97-103. [Katunina EA, Avakyan GN, Titova NV, et al. Levodopa – from creation to new developments. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2010;(4)110:97-103. (In Russ.)].Катунина ЕА, Авакян ГН, Титова НВ и др. Леводопа – от создания к новым разработкам. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010;(4)110:97-103. [Katunina EA, Avakyan GN, Titova NV, et al. Levodopa – from creation to new developments. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2010;(4)110:97-103. (In Russ.)].Karstaedt PJ, Pincus JH. Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol. 1992 Feb;49(2):149-51.Karstaedt PJ, Pincus JH. Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol. 1992 Feb;49(2):149-51.Голубев ВЛ, Левин ЯИ, Вейн АМ. Болезнь Паркинсона и синдром паркинсонизма. Москва: Медпресс; 1999. 415 с. [Golubev VL, Levin YaI, Vein AM. Bolezn' Parkinsona i sindrom parkinsonizma [Parkinson's disease and Parkinsonian syndrome]. Moscow: Medpress; 1999. 415 p.]Голубев ВЛ, Левин ЯИ, Вейн АМ. Болезнь Паркинсона и синдром паркинсонизма. Москва: Медпресс; 1999. 415 с. [Golubev VL, Levin YaI, Vein AM. Bolezn' Parkinsona i sindrom parkinsonizma [Parkinson's disease and Parkinsonian syndrome]. Moscow: Medpress; 1999. 415 p.]Шток ВН, Федорова НВ. Болезнь Паркинсона. Экстрапирамидные расстройства: Руководство по диагностике и лечению. Под ред. В.Н. Штока. Москва: Медпрессинформ; 2002. С. 87-124. [Shtok VN, Fedorova NV. Bolezn' Parkinsona. Ekstrapiramidnye rasstroistva: Rukovodstvo po diagnostike i lecheniyu [Parkinson's Disease. Extrapyramidal disorders: a Guide to diagnosis and treatment]. Shtok VN, editor. Moscow: Medpress-inform; 2002. P. 87-124.]Шток ВН, Федорова НВ. Болезнь Паркинсона. Экстрапирамидные расстройства: Руководство по диагностике и лечению. Под ред. В.Н. Штока. Москва: Медпрессинформ; 2002. С. 87-124. [Shtok VN, Fedorova NV. Bolezn' Parkinsona. Ekstrapiramidnye rasstroistva: Rukovodstvo po diagnostike i lecheniyu [Parkinson's Disease. Extrapyramidal disorders: a Guide to diagnosis and treatment]. Shtok VN, editor. Moscow: Medpress-inform; 2002. P. 87-124.]Яхно НН. Современные подходы к лекарственному лечению болезни Паркинсона. Клиническая фармакология и терапия. 1994;(3-4):92-7. [Yakhno NN. Modern approaches to drug treatment of Parkinson's disease. Klinicheskaya farmakologiya i terapiya. 1994;(3-4):92-7. (In Russ.)].Яхно НН. Современные подходы к лекарственному лечению болезни Паркинсона. Клиническая фармакология и терапия. 1994;(3-4):92-7. [Yakhno NN. Modern approaches to drug treatment of Parkinson's disease. Klinicheskaya farmakologiya i terapiya. 1994;(3-4):92-7. (In Russ.)].Clarke CE, Davies P. Systematic review of acute levodopa and aponorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2000 Nov;69(5):590-4.Clarke CE, Davies P. Systematic review of acute levodopa and aponorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2000 Nov;69(5):590-4.Fahn S; Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson disease? J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42.Fahn S; Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson disease? J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42.Kondo T. Levodopa therapy from the neuroprotection viewpoint. J Neurol. 2005 Oct;252 Suppl 4: IV32- IV36.Kondo T. Levodopa therapy from the neuroprotection viewpoint. J Neurol. 2005 Oct;252 Suppl 4: IV32- IV36.Olanow CW. Levodopa: Effect on cell death and natural history of Parkinson’s disease. Mov Disord. 2015 Jan;30(1):37-44. doi: 10.1002/mds.26119. Epub 2014 Dec 11.Olanow CW. Levodopa: Effect on cell death and natural history of Parkinson’s disease. Mov Disord. 2015 Jan;30(1):37-44. doi: 10.1002/mds.26119. Epub 2014 Dec 11.Schrag A, Hovris A, Morley D, et al. Young vs old onset Parkinson’s disease: Impact of disease and psychosocial consequences. Mov Disord. 2015 Jan;30(1):37-44. doi: 10.1002/mds.26119. Epub 2014 Dec 11.Schrag A, Hovris A, Morley D, et al. Young vs old onset Parkinson’s disease: Impact of disease and psychosocial consequences. Mov Disord. 2015 Jan;30(1):37-44. doi: 10.1002/mds.26119. Epub 2014 Dec 11.Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3- hydroxytyramine) in human brain: Their behaviour in extrapyramidal system diseases. Klin Wochenschr. 1960 Dec 15;38:1236-9.Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3- hydroxytyramine) in human brain: Their behaviour in extrapyramidal system diseases. Klin Wochenschr. 1960 Dec 15;38:1236-9.Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord. 2001 Oct;8(2):95-100.Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord. 2001 Oct;8(2):95-100.Левин ОС, Федорова НВ. Болезнь Паркинсона. Москва: Медпресс-информ; 2012. С. 170-90. [Levin OS, Fedorova NV. Bolezn' Parkinsona [Parkinson's disease]. Moscow: Medpress-inform; 2012. P. 170-90.]Левин ОС, Федорова НВ. Болезнь Паркинсона. Москва: Медпресс-информ; 2012. С. 170-90. [Levin OS, Fedorova NV. Bolezn' Parkinsona [Parkinson's disease]. Moscow: Medpress-inform; 2012. P. 170-90.]Holloway R, Marek K, Biglan K, et al. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009 May;66(5):563-70. doi: 10.1001/archneur.66.1.nct90001.Holloway R, Marek K, Biglan K, et al. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009 May;66(5):563-70. doi: 10.1001/archneur.66.1.nct90001.Aquino CC. Clinical spectrum of levodopainduced complications. Mov Disord. 2015 Jan;30(1):80-9. doi: 10.1002/mds.26125. Epub 2014 Dec 8.Aquino CC. Clinical spectrum of levodopainduced complications. Mov Disord. 2015 Jan;30(1):80-9. doi: 10.1002/mds.26125. Epub 2014 Dec 8.Kirsch-Darrow L, Fernandez HH, Marsiske M. Dissociating apathy and depression in Parkinson’s disease. Neurology. 2006 Jul 11;67(1):33-8.Kirsch-Darrow L, Fernandez HH, Marsiske M. Dissociating apathy and depression in Parkinson’s disease. Neurology. 2006 Jul 11;67(1):33-8.Сilia R, Akpalu A, Stephen Sarfo F. The modern prelevodopa era of Parkinson disease: insights into motor complications from sub-Suharan Africa. Brain. 2014 Oct;137 (Pt 10):2731-42. doi: 10.1093/brain/awu195. Epub 2014 Jul 17.Сilia R, Akpalu A, Stephen Sarfo F. The modern prelevodopa era of Parkinson disease: insights into motor complications from sub-Suharan Africa. Brain. 2014 Oct;137 (Pt 10):2731-42. doi: 10.1093/brain/awu195. Epub 2014 Jul 17.Thenganatt MA, Jancovic J. Parkinson disease subtypes. JAMA Neurol. 2014 Apr;71(4):499-504. doi: 10.1001/jamaneurol.2013.6233.Thenganatt MA, Jancovic J. Parkinson disease subtypes. JAMA Neurol. 2014 Apr;71(4):499-504. doi: 10.1001/jamaneurol.2013.6233.Ku S, Glass GA. Age of Parkinson’s disease onset as a predictor for the development of diskinesia. Mov Disord. 2010 Jul 15;25(9): 1177-82. doi: 10.1002/mds.23068.Ku S, Glass GA. Age of Parkinson’s disease onset as a predictor for the development of diskinesia. Mov Disord. 2010 Jul 15;25(9): 1177-82. doi: 10.1002/mds.23068.Hassan-Baer S, Molchadski I, Cohen OS. Gender effect on time to levodopa-induced dyskinesias. J Neurol. 2011 Nov;258(11): 2048-53. doi: 10.1007/s00415-011-6067-0. Epub 2011 May 1.Hassan-Baer S, Molchadski I, Cohen OS. Gender effect on time to levodopa-induced dyskinesias. J Neurol. 2011 Nov;258(11): 2048-53. doi: 10.1007/s00415-011-6067-0. Epub 2011 May 1.Lee JY, Cho J, Lee EK, et al. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson’s disease. Mov Disord. 2011 Jan;26(1):73-9. doi: 10.1002/mds.23400. Epub 2010 Oct 13.Lee JY, Cho J, Lee EK, et al. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson’s disease. Mov Disord. 2011 Jan;26(1):73-9. doi: 10.1002/mds.23400. Epub 2010 Oct 13.Schumacher-Schuh AF, Altmann V, Rieck M, et al. Association of common genetic variants of HOMER 1 gene with levodopa adverse effects in Parkinson’s disease. Pharmacogenomics J. 2014 Jun;14(3):289-94. doi: 10.1038/tpj.2013.37. Epub 2013 Oct 15.Schumacher-Schuh AF, Altmann V, Rieck M, et al. Association of common genetic variants of HOMER 1 gene with levodopa adverse effects in Parkinson’s disease. Pharmacogenomics J. 2014 Jun;14(3):289-94. doi: 10.1038/tpj.2013.37. Epub 2013 Oct 15.Fahn S, Oakes D, Shoulson I, et al. Levodopa and progression of Parkinson’s disease. N Engl J Med. 2004 Dec 9;351(24):2498-508.Fahn S, Oakes D, Shoulson I, et al. Levodopa and progression of Parkinson’s disease. N Engl J Med. 2004 Dec 9;351(24):2498-508.Pakkenberg H, Birket-Smith E, Dupont E, et al. Parkinson’s disease treated with Sinemet or Madopar. A controlled multicenter trial. Acta Neurol Scand. 1976 May;53(5):376-85.Pakkenberg H, Birket-Smith E, Dupont E, et al. Parkinson’s disease treated with Sinemet or Madopar. A controlled multicenter trial. Acta Neurol Scand. 1976 May;53(5):376-85.Rinne UK, Molsa P. Levodopa with benserazide or carbidopa in Parkinson’s disease. Neurology. 1979 Dec;29(12):1584-9.Rinne UK, Molsa P. Levodopa with benserazide or carbidopa in Parkinson’s disease. Neurology. 1979 Dec;29(12):1584-9.Brod LS, Aldred JL, Nutt JG. Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson’s disease. Neurology. 1979 Dec;29(12):1584-9.Brod LS, Aldred JL, Nutt JG. Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson’s disease. Neurology. 1979 Dec;29(12):1584-9.

The authors declare that there are no conflicts of interest present.